BeiGene of Beijing has treated the first patient in China Phase I trial of BGB-290, a PARP inhibitor. The trial will administer BGB-290 to patients with advanced solid tumors. Two and a half years ago, BeiGene started its first trial of the drug in Australia, and it has reported positive early data from the test. One of the primary targets of BGB-290 will be ovarian cancer, and BeiGene also plans to pair the PARP inhibitor with its PD-1 immuno-oncology candidate in future trials.
